Diabetes 68 , 906917 (2019)
Its structure features two key modifications that set it apart: An arginine substitution at the third position A 13-amino acid extension at the N-terminus This unique molecular architecture results in a more stable compound with a molecular weight of approximately 9.1 kDa, specifically designed to optimize its performance within the human body
doi: 10.1017/S109285292100002X
Wu, H., Lin, L., Giblin, F., Ho, Y
Don't discontinue or switch medications without medical guidance
Expanding Applications: Clinical trials are actively investigating the use of GLP-1 RAs for a wider range of conditions, including addiction, kidney disease, and neurodegenerative disorders, based on their broad physiological effects